{
    "2021-12-22": [
        [
            {
                "time": "2023-10-01",
                "original_text": "Novartis Cosentyx® receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis",
                "features": {
                    "keywords": [
                        "Cosentyx",
                        "FDA approval",
                        "children",
                        "adolescents",
                        "enthesitis-related arthritis",
                        "psoriatic arthritis"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year",
                "features": {
                    "keywords": [
                        "Leqvio",
                        "FDA approval",
                        "cholesterol",
                        "siRNA"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "TBJ Plus: New CEO takes helm at Durham pharma; $1.5B deal has Triangle link; Big name change in Wilmington",
                "features": {
                    "keywords": [
                        "CEO",
                        "Durham pharma",
                        "$1.5B deal",
                        "Triangle link",
                        "Wilmington"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "management"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Novartis to Buy Gene-Therapy Company Targeting Eye Condition",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Gene-Therapy",
                        "Eye Condition"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Novartis (NVS) to Buy Gyroscope, Submits Herceptin Biosimilar to EMA",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Gyroscope",
                        "Herceptin",
                        "Biosimilar",
                        "EMA"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Novartis Agrees to Acquire Gyroscope Therapeutics for $1.5 Billion",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Acquire",
                        "Gyroscope Therapeutics",
                        "$1.5 Billion"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Novartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Gyroscope Therapeutics",
                        "gene therapy",
                        "geographic atrophy",
                        "blindness"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Sandoz submits Marketing Authorization Application for proposed biosimilar trastuzumab to EMA",
                "features": {
                    "keywords": [
                        "Sandoz",
                        "Marketing Authorization Application",
                        "biosimilar",
                        "trastuzumab",
                        "EMA"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}